2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    PI3K/Akt/mTOR
  4. ATM/ATR
  5. ATM/ATR Inhibitor

ATM/ATR Inhibitor

ATM/ATR Isoform Comparison

ATM/ATR Inhibitors (67):

Cat. No. Product Name Effect Purity
  • HY-111783
    AZD-7648
    		Inhibitor 99.86%
    AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity.
  • HY-19323
    Ceralasertib
    		Inhibitor 99.76%
    Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of ATR kinase with an IC50 of 1 nM.
  • HY-12016
    KU-55933
    		Inhibitor 99.92%
    KU-55933 is a potent ATM inhibitor with an IC50 and Ki of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
  • HY-12061
    KU-60019
    		Inhibitor 99.43%
    KU-60019 is an improved ATM kinase-specific inhibitor with IC50 of 6.3 nM.
  • HY-109566
    AZD1390
    		Inhibitor 99.28%
    AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC50 of 0.78 nM in cell.
  • HY-P10280
    ATR kinase substrate peptide
    		Inhibitor 99.17%
    ATR kinase substrate peptide (compound 45) is a potent and selective inhibitor of ATR (Ataxia Telangiectasia and Rad3 related) protein kinase (Ki=6 nM). ATR kinase substrate peptide inhibits ATR activity by competing with ATR kinase ATP-binding sites to block ATR mediated signaling. ATR kinase substrate peptide can be used to study the role of ATR kinase in DNA damage response.
  • HY-161838
    ICT10336
    		Inhibitor
    ICT10336 is a hypoxia-responsive prodrug of ATR inhibitor, AZD6738 (HY-19323). ICT10336 is hypoxia-activated and specifically releases AZD6738 only in hypoxic conditions in vitro. This can inhibit ATR activation (T1989 and S428 phosphorylation) and subsequently abrogate HIF1a-mediated adaptation of hypoxic cancers cells, thus selectively inducing cell death in 2D and 3D cancer models. ICT10336 is a metabolic substrate of CYPOR activity.
  • HY-101566
    Elimusertib
    		Inhibitor 99.99%
    Elimusertib (BAY-1895344) is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib has anti-tumor activity. Elimusertib can be used for the research of solid tumors and lymphomas.
  • HY-14731
    VE-821
    		Inhibitor 98.32%
    VE-821 is a potent ATP-competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM.
  • HY-100016
    AZD0156
    		Inhibitor 99.83%
    AZD0156 is a potent, selective and orally active ATM inhibitor with an IC50 of 0.58 nM. AZD0156 inhibits the ATM-mediated signaling, prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis.
  • HY-139609
    Camonsertib
    		Inhibitor 99.75%
    Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity.
  • HY-13902
    Berzosertib
    		Inhibitor 99.70%
    Berzosertib (VE-822) is an ATR inhibitor with a Ki value of less than 0.2 nM. It also inhibits ATM with a Ki of 34 nM.
  • HY-117693
    Mirin
    		Inhibitor 98.12%
    Mirin is a potent Mre11-Rad50-Nbs1 (MRN) complex inhibitor. Mirin prevents MRN-dependent activation of ATM (IC50=12 μM) without affecting ATM protein kinase activity, and it inhibits Mre11-associated exonuclease activity. Mirin abolishes the G2/M checkpoint and homology-dependent repair in mammalian cells. Mirin prevents ATM activation in response to DNA double-strand breaks (DSBs) and blocks homology-directed repair (HDR) in mammalian cells.
  • HY-15557
    AZ20
    		Inhibitor 99.40%
    AZ20 is a potent and selective inhibitor of ATR with an IC50 of 5 nM, and has 8-fold selectivity against mTOR (IC50=38 nM).
  • HY-136270
    Gartisertib
    		Inhibitor 99.76%
    Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a Ki of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC50 of 8 nM. Antitumor activity.
  • HY-111451
    Tuvusertib
    		Inhibitor 99.77%
    Tuvusertib (M1774; ATR inhibitor 1) is a selective and orally active ATR inhibitor extracted from patent WO2015187451A1, compound I-l, with a Ki value below 1 μΜ.
  • HY-101566A
    Elimusertib hydrochloride
    		Inhibitor 99.85%
    Elimusertib (BAY 1895344) hydrochloride is a potent, orally active and selective ATR inhibitor with an IC50 of 7 nM. Elimusertib hydrochloride has anti-tumor activity. Elimusertib hydrochloride can be used for the research of solid tumors and lymphomas.
  • HY-150617
    Lartesertib
    		Inhibitor 99.89%
    Lartesertib (M4076) is a potent inhibitor of serine/threonine protein kinase ATM (extracted from patent WO2022058351A1).
  • HY-19959
    (Z)-Mirin
    		Inhibitor 99.30%
    (Z)-Mirin is an MRN (Mre11-Rad50-Nbs1) inhibitor. (Z)-Mirin prevents MRN-dependent activation of ATM without affecting ATM protein kinase activity. (Z)-Mirin inhibits Mre11-associated exonuclease activity. (Z)-Mirin increases apoptosis, triggers a G2/M checkpoint and strongly inhibits homology-directed repair (HDR).
  • HY-15520
    CGK733
    		Inhibitor 99.83%
    CGK733 is a potent ATM/ATR inhibitor, used for the research of cancer.